The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids

International Journal of Neuropsychopharmacology

Volumn 14, Issue 5, 2011, Pages 631-643

  Boucher, Aurélie A ^a,b,c   Hunt, Glenn E ^a   Micheau, Jacques ^c   Huang, Xufeng ^b,d   McGregor, Iain S ^a   Karl, Tim ^b,e,f   Arnold, Jonathon C ^a,b,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITY OF WOLLONGONG   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^g University of Sydney   (Australia)

Author keywords

Cannabinoid; Fos; neuregulin; schizophrenia; tolerance

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; NEU DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; GENE; GENE FUNCTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HYPOTHERMIA; LOCOMOTION; MALE; MOUSE; NONHUMAN; NRG 1 GENE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; STARTLE REFLEX;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; CANNABINOIDS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; DRUG TOLERANCE; EXPLORATORY BEHAVIOR; GENOTYPE; HETEROZYGOTE; MALE; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; NEUREGULIN-1; PROTO-ONCOGENE PROTEINS C-FOS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; STARTLE REACTION; TETRAHYDROCANNABINOL;

EID: 79956013167     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571000091X     Document Type: Article

References (55)

1. Arnold JC, Hunt GE, McGregor IS (2001a). Effects of the cannabinoid receptor agonist CP55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sciences 70, 97-108. (Pubitemid 33124358)
2. Arnold JC, Topple AN, Hunt GE, McGregor IS (1998). Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP55,940 on behavioral sensitization to cocaine. European Journal of Pharmacology 354, 9-16. (Pubitemid 28410225)
3. Arnold JC, Topple AN, Mallet PE, Hunt GE, et al. (2001b). The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research 921, 240-255. (Pubitemid 33096304)
4. Berrendero F, Maldonado R (2002). Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berlin) 163, 111-117. (Pubitemid 34985320)
5. Boucher AA, Arnold JC, Duffy L, Schofield PR, et al. (2007a). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berlin) 192, 325-336. (Pubitemid 46705399)
6. Boucher AA, Hunt GE, Karl T, Micheau J, et al. (2007b). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol- induced c-Fos expression. Neuroscience 149, 861-870. (Pubitemid 350122892)
7. Boucher AA, Vivier L, Metna-Laurent M, Brayda-Bruno L, et al. (2009). Chronic treatment with Delta(9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. Behavioural Pharmacology 20, 45-55.
8. Caberlotto L, Rimondini R, Hansson A, Eriksson S, et al. (2004). Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? Neuropsychopharmacology 29, 15-22. (Pubitemid 38068009)
9. Caspi A, Moffitt TE, Cannon M, McClay J, et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 1117-1127. (Pubitemid 40615773)
10. Costa B, Parolaro D, Colleoni M (1996). Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. European Journal of Pharmacology 313, 17-24. (Pubitemid 26342201)
11. Costall B, Jones BJ, Kelly ME, Naylor RJ, et al. (1989). Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacology, Biochemistry and Behavior 32, 777-785. (Pubitemid 19162403)
12. Crawley JN (1985). Exploratory behavior models of anxiety in mice. Neuroscience and Biobehavioral Reviews 9, 37-44. (Pubitemid 15136669)
13. Crawley JN (1999). Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Research 835, 18-26. (Pubitemid 29336546)
14. D'Souza DC, Perry E, MacDougall L, Ammerman Y, et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572. (Pubitemid 38982249)
15. Dean B, Karl T, Pavey G, Boer S, et al. (2008). Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophrenia Research 99, 341-349. (Pubitemid 351249119)
16. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15. (Pubitemid 32304342)
17. DeFries JC, Hegmann JP, Weir MW (1966). Open-field behavior in mice: evidence for a major gene effect mediated by the visual system. Science 154, 1577-1579.
18. Denenberg VH (1969). Open-field behavior in the rat: what does it mean? Annals of the New York Academy of Sciences 159, 852-859.
19. Fan F, Tao Q, Abood M, Martin BR (1996). Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP55,940 on adenylyl cyclase in the cerebellum of CP55,940-tolerant mice. Brain Research 706, 13-20. (Pubitemid 26032220)
20. File SE (1988). How good is social interaction as a test of anxiety? In: Simon P, Soubrié P, Wildlocher D (Eds), Animal Models of Psychiatric Disorders. Selected Models of Anxiety, Depression and Psychosis (pp. 151-166). Basel: Karger.
21. Frischknecht HR, Sieber B, Waser PG (1982). Effects of multiple, chronic and early hashish exposure on mating behavior, nest-building and gestation in mice. Comparative Biochemistry and Physiology, Part C 72, 363-368. (Pubitemid 12020252)
22. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M (2009). The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience 259, 371-382.
23. Gold LH, Balster RL, Barrett RL, Britt DT, et al. (1992). A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP55,940 in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 262, 479-486.
24. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacology Biochemistry and Behavior 81, 300-318. (Pubitemid 40807129)
25. Henquet C, Di Forti M, Morrison P, Kuepper R, et al. (2008). Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111-1121.
26. Henquet C, Murray R, Linszen D, van Os J (2005). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608-612. (Pubitemid 41253312)
27. Henquet C, Rosa A, Delespaul P, Papiol S, et al. (2009). COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatrica Scandinavica 119, 156-160.
28. Hill MN, Gorzalka BB (2004). Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. European Journal of Pharmacology 499, 291-295. (Pubitemid 39233668)
29. Hughes P, Dragunow M (1995). Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacological Reviews 47, 133-178.
30. Karl T, Duffy L, ScimoneA, Harvey RP, et al. (2007). Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes, Brain and Behavior 6, 677-687. (Pubitemid 47476190)
31. Kask A, Nguyen HP, Pabst R, von Horsten S (2001). Factors influencing behavior of group-housed male rats in the social interaction test: focus on cohort removal. Physiology & Behavior 74, 277-282. (Pubitemid 33070399)
32. Keri S, Kiss I, Seres I, Kelemen O (2009). A polymorphism of the neuregulin 1 gene (SNP8NRG243177/rs6994992) affects reactivity to expressed emotion in schizophrenia. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 150B, 418-420.
33. Leweke FM, Giuffrida A, Koethe D, Schreiber D, et al. (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29-36. (Pubitemid 47031599)
34. Leweke FM, Koethe D (2008). Cannabis and psychiatric disorders: it is not only addiction. Addiction Biology 13, 264-275. (Pubitemid 351692982)
35. Linszen DH, Dingemans PM, Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273-279. (Pubitemid 24127299)
36. Malone DT, Kearn CS, Chongue L, Mackie K, et al. (2008). Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats. Neuroscience 152, 265-272.
37. Malone DT, Taylor DA (2006). The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behavioural Brain Research 166, 101-109. (Pubitemid 41677366)
38. Martin RS, Secchi RL, Sung E, Lemaire M, et al. (2003). Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berlin) 165, 128-135. (Pubitemid 36056989)
39. McGregor IS, Issakidis CN, Prior G (1996). Aversive effects of the synthetic cannabinoid CP55,940 in rats. Pharmacology, Biochemistry and Behavior 53, 657-664. (Pubitemid 26088545)
40. Nagai H, Egashira N, Sano K, Ogata A, et al. (2006). Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacology, Biochemistry and Behavior 84, 330-336. (Pubitemid 44107489)
41. Nestler EJ, Kelz MB, Chen J (1999). DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Research 835, 10-17. (Pubitemid 29336545)
42. Oliva JM, Ortiz S, Palomo T, Manzanares J (2004). Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain. Journal of Psychopharmacology 18, 59-65. (Pubitemid 38623095)
43. Perrotti LI, Hadeishi Y, Ulery PG, Barrot M, et al. (2004). Induction of deltaFosB in reward-related brain structures after chronic stress. Journal of Neuroscience 24, 10594-10602. (Pubitemid 39557632)
44. Rodgers RJ (1997). Animal models of 'anxiety': where next? Behavioural Pharmacology 8, 477-496. (Pubitemid 27504695)
45. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, et al. (1996). Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Journal of Pharmacology and Experimental Therapeutics 276, 56-64.
46. Rubino T, Patrini G, Parenti M, Massi P, et al. (1997). Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Research. Molecular Brain Research 44, 191-197. (Pubitemid 27102847)
47. Saddichha S, Sur S, Sinha BN, Khess CR (2010). How is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis. Substance Abuse 31, 58-67.
48. Schneider M, Koch M (2002). The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behavioural Pharmacology 13, 29-37. (Pubitemid 34174529)
49. Sheehan TP, Chambers RA, Russell DS (2004). Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Research Reviews 46, 71-117. (Pubitemid 39036164)
50. Staples LG, McGregor IS, Hunt GE (2009). Long-lasting FosB/DeltaFosB immunoreactivity in the rat brain after repeated cat odor exposure. Neuroscience Letters 462, 157-161.
51. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 71, 877-892. (Pubitemid 135750519)
52. Ujike H, Takaki M, Nakata K, Tanaka Y, et al. (2002). CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Molecular Psychiatry 7, 515-518. (Pubitemid 34712904)
53. Viveros MP, Marco EM, File SE (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior 81, 331-342. (Pubitemid 40807131)
54. Wang JH, Short J, Ledent C, Lawrence AJ, et al. (2003). Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behavioural Brain Research 143, 201-207. (Pubitemid 36937165)
55. Whitlow CT, Freedland CS, Porrino LJ (2003). Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug and Alcohol Dependence 71, 169-177. (Pubitemid 37289026)